Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2015 (2015), Article ID 794592, 4 pages
http://dx.doi.org/10.1155/2015/794592
Case Report

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy

1Division of Pulmonary and Critical Care, Albany Medical Center, Albany, NY, USA
2Division of Pulmonary and Critical Care, National Jewish Health, Denver, CO, USA
3Division of Pulmonary and Critical Care, Cleveland Clinic, Cleveland, OH, USA
4Division of Pulmonary and Critical Care, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Received 28 November 2014; Accepted 14 January 2015

Academic Editor: Kentaro Watanabe

Copyright © 2015 Amit Chopra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. Pegylated interferon α and ribavirin combination is the mainstay of treatment. Severe pulmonary toxicities are rarely reported. We report here a case of severe form of organizing pneumonia secondary to pegylated interferon α therapy presenting as acute respiratory failure. Patient has near complete recovery with withdrawal of pegylated interferon α and steroid therapy. We report this case to raise the awareness of this rare but potentially life-threatening pulmonary complication of pegylated interferon α therapy.